Treatment with Sotrovimab resulted in an 85 percent reduction in the risk of hospitalisation or death in high-risk adult COVID-19 outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial.GSK says exploring all options to make COVID-19 antibody drug Sotrovimab available in India quickly
Treatment with Sotrovimab resulted in an 85 percent reduction in the risk of hospitalisation or death in high-risk adult COVID-19 outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE trial.
Subscribe to:
Post Comments (Atom)
-
"The (latest) investment will be used to grow the mobile esports format and establish presence in select overseas markets through its ...
-
The NCLT#39;s Ahmedabad bench has directed the RP to include GAIL in the list of creditors for both the companies.
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment